Multiple sclerosis (MS) drugs Ocrevus and Gilenya have been linked to melanoma, with Gilenya linked to squamous cell carcinoma and basal cell carcinoma, also. These new drug safety findings come from an analysis of skin cancer cases reported to the FDA Adverse Event Reporting System (FAERS) for patients receiving certain multiple sclerosis (MS) therapies, including the drugs Gilenya, Lemtrada, Mayzent, and Ocrevus.
From the Conclusion part of this medical research article, “S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal”, published by the medical journal Multiple Sclerosis and Related Disorders:
The present study detected a potential safety signal for the S1P receptor modulators [Gilenya (fingolimod)] and [Mayzent (siponimod)] for basal cell carcinomas. [Gilenya (fingolimod)] had also an increased signal of disproportionate reporting for melanoma and squamous cell carcinoma. [Lemtrada (alemtuzumab)] presented also a signal for all three types of skin cancer, while [Ocrevus (ocrelizumab)] presented a potential safety signal for melanoma.
This February 22, 2022, Multiple Sclerosis News Today article, “More Skin Cancer Reported to FDA From Patients on Certain Oral DMTs”, points out these two important facts:
- The findings showed the MS drugs Ocrevus and Gilenya were linked to melanoma skin cancer: and,
- The findings showed Gilenya was linked to squamous cell carcinoma and basal cell carcinoma, also.
We will continue to monitor the safety profile of Ocrevus and Gilenya, as well as Lemtrada and Mayzent, with a focus on the possible increased risks of melanoma, squamous cell carcinoma, and basal cell carcinoma.
[View article at original source]Gilenya | Lemtrada | Mayzent | Ocrevus
Free Case Evaluation
Strictly Confidential, No Obligation